TAMs have a relatively short half-life and are therefore must be replaced continuously by inflammatory monocytes recruited from the bloodstream primarily in response to the chemokine CCL2, produced by tumor cells, tumor fibroblasts, and by myeloid cells (32). The gene discussed is CCL2; the disease is neoplasm.